A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author González Gascón y Marín, Isabelca
  • dc.contributor.author Puiggros Metje, Anna Mariaca
  • dc.contributor.author Espinet Solà, Blancaca
  • dc.contributor.author Hernández, José-Ángelca
  • dc.contributor.author Grupo Español de Leucemia Linfática Crónica (GELLC)ca
  • dc.contributor.author Grupo Cooperativo Español de Citogenética Hematológica (GCECGH)ca
  • dc.date.accessioned 2015-06-02T11:17:25Z
  • dc.date.available 2016-02-28T03:00:04Z
  • dc.date.issued 2014
  • dc.description.abstract The prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients diagnosed with CLL carrying +12. Median OS was 129 months. One hundred seventy-four patients (60.2%) presented +12 in <60% of cells. TTFT and OS for this subgroup were longer than for the subgroup with +12 in ≥60% of cells, with a median TTFT of 49 months (CI95%, 39-58) vs 30 months (CI95%, 22-38) (P = 0.001); and a median OS of 159 months (CI95%, 119-182), vs 96 months (CI95%, 58-134) (P = 0.015). Other factors associated with a shorter TTFT were: Binet stage, B symptoms, lymphadenopathy, splenomegaly, high lymphocyte count, 11q-, high β2 microglobulin, and high LDH. In the multivariate analysis, clinical stage, +12 in ≥60% of cells, high lymphocyte count, B symptoms, and 11q- in addition, resulted of significance in predicting shorter TTFT. Significant variables for OS were: Binet stage, lymphadenopathy, splenomegaly, high LDH, high β2 microglobulin, 11q-, and CD38. In the multivariate analysis, only Binet stage, 11q-, and high β2microglobulin significantly predicted shorter OS. CLL with +12 entails a heterogeneous group with intermediate prognosis. However, a high proportion of cells carrying +12 separates a subgroup of patients with poor outcomeca
  • dc.format.mimetype application/pdfca
  • dc.identifier.citation González-Gascón y Marín I, Hernández-Sánchez M, Rodríguez-Vicente AE, Sanzo C, Aventín A, Puiggros A, et al. A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematol Oncol. 2016;34(2):84-92. doi: 10.1002/hon.2196.ca
  • dc.identifier.doi http://dx.doi.org/10.1002/hon.2196
  • dc.identifier.issn 0278-0232
  • dc.identifier.uri http://hdl.handle.net/10230/23717
  • dc.language.iso engca
  • dc.publisher Wileyca
  • dc.relation.ispartof Hematological Oncology 2016;34(2):84-92
  • dc.rights © 2015 John Wiley & Sons. The definitive version is available online at: http://dx.doi.org/10.1002/hon.2196ca
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.subject.other Hematologiaca
  • dc.subject.other Leucèmiaca
  • dc.title A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemiaca
  • dc.type info:eu-repo/semantics/articleca
  • dc.type.version info:eu-repo/semantics/acceptedVersionca